What is Radformation?
Radformation operates at the intersection of oncology and software engineering, providing a suite of tools designed to streamline the radiation treatment planning process. By replacing manual, time-intensive tasks with standardized, automated workflows, the company empowers clinicians to deliver safer and more consistent care. Its market position is defined by a commitment to democratizing high-quality radiation therapy, ensuring that patients receive optimal treatment regardless of their geographic location or the specific resources available at their local facility. The firm's technology serves as a vital bridge between complex medical data and actionable clinical outcomes, positioning it as a leader in the digital transformation of oncology departments worldwide.
How much funding has Radformation raised?
Radformation has raised a total of $2.6M across 3 funding rounds:
Private Equity
$663K
Angel/Seed
$1.6M
Debt
$350K
Private Equity (2017): $663K, investors not publicly disclosed
Angel/Seed (2018): $1.6M led by Brooklyn Bridge Ventures
Debt (2020): $350K supported by PPP
Key Investors in Radformation
Brooklyn Bridge Ventures
Brooklyn Bridge Ventures is a venture capital firm specializing in early-stage investments, providing essential support to startups as they navigate the initial phases of market entry and product development.
Undisclosed Investor
Undisclosed investor participating in the funding round.
PPP
Public-Private Partnership
What's next for Radformation?
Looking ahead, Radformation is poised to leverage its recent capital to scale its software ecosystem and expand its footprint in international markets. The strategic focus will likely remain on enhancing the interoperability of its platform with existing hospital information systems, thereby reducing the friction associated with adopting new medical technologies. As the company continues to refine its algorithms, the emphasis will shift toward long-term clinical efficacy and the integration of predictive analytics to further personalize patient treatment plans. By maintaining its focus on operational efficiency and clinical safety, Radformation is well-positioned to sustain its growth and continue its mission of reducing the global impact of cancer through technological innovation.
See full Radformation company page
